Auranofin Attenuates Non-Alcoholic Fatty Liver Disease by Suppressing Lipid Accumulation and NLRP3 Inflammasome-Mediated Hepatic Inflammation In Vivo and In Vitro

• Main Authors: Hyun Hwangbo (Author), Min Yeong Kim (Author), Seon Yeong Ji (Author), So Young Kim (Author), Hyesook Lee (Author), Gi-Young Kim (Author), Cheol Park (Author), Young-Sam Keum (Author), Su Hyun Hong (Author), Jaehun Cheong (Author), Yung Hyun Choi (Author)
• Format: Book
• Published: MDPI AG, 2020-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Non-alcoholic fatty liver disease (NAFLD) causes liver dysfunction and is associated with obesity and type 2 diabetes. Chronic inflammation is associated not only with the development of NAFLD, but also with hepatic diseases, including steatohepatitis, cirrhosis, and hepatocellular carcinoma. Aurano...